Beneath the surface, what is forming is a regulatory sorting mechanism — and today's data gives it sharper teeth. The ibogaine cardiac papers will almost certainly become the evidentiary foundation for an FDA guidance document requiring mandatory cardiac screening protocols before any IND expansion proceeds. That guidance, when it arrives, will delay veteran-focused ibogaine trials by twelve to eighteen months — not cancel them, delay them. The distinction matters enormously. Meanwhile, the psilocybin RCT accumulation is performing a different kind of work: it is building the citation architecture that accelerated approval applications require, while simultaneously surfacing the granular mechanistic questions — extinction without relapse prevention, short-term efficacy without long-term outcome data — that will shape exactly what FDA asks for next. Both channels are moving toward the same structural moment: a mid-2027 regulatory decision point at which the evidence base either clears the bar or reveals which gaps remain. The highest trajectory from here is not frictionless — it runs directly through the friction, which is why the friction itself is meaningful.
Somewhere tonight there is a veteran who has been through six rounds of standard-of-care treatment for PTSD and is watching the ibogaine news with the particular exhaustion of someone who has learned not to count on timelines. There is a clinician in a ketamine practice who is fielding calls from patients who cannot afford the gap between what is FDA-approved and what the evidence suggests might help them more. There is a family that has been holding space around someone with treatment-resistant depression for three years, reading every RCT summary they can find, trying to understand what "accelerated approval" means in real time. What the current data genuinely supports for all of them is this: the evidence base is not stalling — it is maturing, which is a different thing. The cardiac safety work, the mechanism work, the RCT accumulation — these are not obstacles to the highest timeline. They are the highest timeline building itself out of exactly the right materials.
Every authentic ceremony is a reclamation — of the body, the breath, the forgotten self. OOTW exists to hold space for that reclamation as the science arrives to name it.
The intelligence that created you is still creating.
62%
FDA demands heart screening before ibogaine trials expand
The FDA (US drug regulator) will require companies to do cardiac screening tests before expanding ibogaine studies, because recent research shows ibogaine can affect heart rhythm. This slows down trials — especially ones for veterans — by over a year.
→ Heart safety concerns will force the FDA to add screening requirements that delay ibogaine research by over a year.
Resolves: 2027-03-01 · USA
REGULATORY
the precise call ▾
FDA will issue formal ibogaine cardiac safety guidance requiring mandatory cardiac screening protocols before any IND expansion, delaying veteran-focused trials by 12-18 months. Recent dual ibogaine cardiac safety papers on QT prolongation and arrhythmia provide FDA's safety division with documented grounds to impose enhanced cardiac monitoring requirements before IND expansion. Procedurally consistent with FDA's liability calculus on novel Schedule I compounds with known c
38%
Two companies will ask FDA for fast-track psilocybin approval
Psilocybin therapy companies have good clinical trial data on depression and suicidal thoughts. Two of them will ask the FDA (US drug regulator) for an expedited approval process called 'accelerated approval,' which is faster than normal. But the FDA may say no because of how hard it is to run psilocybin trials fairly.
→ Two companies will ask the FDA for fast-track psilocybin approval by late 2027, but the FDA probably won't grant it.
Resolves: 2027-11-01 · USA
REGULATORY
the precise call ▾
At least two sponsors will submit accelerated approval pathway applications to FDA for psilocybin-based therapies by November 2027. RCT data on MDD, suicidal ideation, and cocaine use disorder constitutes a meaningful evidentiary advance, but accelerated approval requires demonstration of effect on a surrogate or intermediate endpoint reasonably likely to predict clinical benefit — psilocybin trials have historically struggled w
61%
Three non-psychedelic ibogaine drugs will start lab testing
Researchers will start developing versions of ibogaine that don't make you hallucinate but keep the healing effects by targeting brain plasticity. Companies will invest in these because they're easier to regulate and market.
→ Researchers will develop versions of ibogaine without hallucinations within 3 years, driven by brain-rewiring science.
Resolves: 2029-05-01 · Global
RESEARCH
the precise call ▾
At least three non-hallucinogenic structural ibogaine analogues will enter preclinical development within 36 months, driven by neuroplasticity mechanism findings. BDNF/TrkB-mediated juvenile-like plasticity induction is a well-characterized drug discovery target that reliably attracts medicinal chemistry investment. Visual cortex plasticity data provides a quantifiable preclinical endpoint. However, 'preclinical development' must mean documented IND-enabling
57%
Congress forms psychedelic study group before 2027, no laws until 2028
Congress will create an official commission to study psychedelic medicine—likely tucked into the National Defense Authorization Act (NDAA), which funds the military—because both parties like supporting veterans. But nobody will actually change drug laws or let doctors prescribe psychedelics before 2028.
→ Congress will officially study psychedelic medicine before 2027, but won't change drug laws until 2028 or later.
Resolves: 2026-12-31 · USA
LEGISLATION
the precise call ▾
A formal congressional study commission on psychedelic medicine will be established via NDAA or standalone legislation before end of 2026, but no scheduling or prescribing legislation will pass before 2028. Study commission via NDAA is the lowest-resistance federal action: bipartisan veteran appeal, no DEA scheduling trigger, precedent in prior NDAA psychedelic provisions (FY2024 ibogaine study language). The two-part structure is falsifiable — commission establishment and absence of scheduling legisla